Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities

Affiliations

¹ Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
² Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
³ Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
⁴ Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
⁵ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
⁶ Department of Internal Medicin, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
⁷ Department of Hematology, South Elvsborg Hospital, Borås, Sweden.
⁸ Department of Hematology, St Olavs Hospital/Norwegian University of Science and Technology, Trondheim, Norway.
⁹ Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. s.zweegman@amsterdamumc.nl.

^# Contributed equally.

Comment

Claudia A M Stege et al. Leukemia. 2020 Jul.

. 2020 Jul;34(7):1964-1966.

doi: 10.1038/s41375-020-0713-4. Epub 2020 Jan 22.

¹ Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
² Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
³ Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
⁴ Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
⁵ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
⁶ Department of Internal Medicin, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
⁷ Department of Hematology, South Elvsborg Hospital, Borås, Sweden.
⁸ Department of Hematology, St Olavs Hospital/Norwegian University of Science and Technology, Trondheim, Norway.
⁹ Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. s.zweegman@amsterdamumc.nl.

^# Contributed equally.

No abstract available

Comment on

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J. Facon T, et al. Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19. Leukemia. 2020. PMID: 31427722 Free PMC article. Clinical Trial.

1. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068–74. - DOI
1. Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2019;34:224–33. - DOI
1. Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 2016;127:1109–16. - DOI